Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

1.79
-0.1400-7.25%
Post-market: 1.790.00000.00%19:58 EDT
Volume:26.82M
Turnover:48.39M
Market Cap:597.74M
PE:-1.45
High:1.98
Open:1.98
Low:1.72
Close:1.93
Loading ...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
13 Feb

Iovance Biotherapeutics appoints Kirby as Chief Commercial Officer

TIPRANKS
·
10 Feb

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

GlobeNewswire
·
10 Feb

Iovance Biotherapeutics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
31 Jan

Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler

TIPRANKS
·
31 Jan

Truist Financial Releases a Buy Rating on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
30 Jan

Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment

TIPRANKS
·
28 Jan

Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics

Simply Wall St.
·
24 Jan

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
18 Jan

Wells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
16 Jan

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)

TIPRANKS
·
12 Jan

Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing

Insider Monkey
·
02 Jan

BRIEF-Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
21 Dec 2024

Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
21 Dec 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
21 Dec 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%

Simply Wall St.
·
03 Dec 2024

Iovance Biotherapeutics promotes Raj Puri to chief regulatory officer

TIPRANKS
·
27 Nov 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.d., Ph.d. to Chief Regulatory Officer

THOMSON REUTERS
·
27 Nov 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

GlobeNewswire
·
27 Nov 2024

Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey
·
23 Nov 2024